Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.
April W ArmstrongMatthias AugustinJennifer L BeaumontTan P PhamStacie HudgensKenneth B GordonJoe ZhuoBrandon BeckerYichen ZhongRenata M KisaSubhashis BanerjeeKim A PappPublished in: Dermatology and therapy (2024)
NCT03624127, NCT03611751.